Genentech announced the FDA has approved ranibizumab 100 mg/mL injection for wet age-related macular degeneration in patients who previously responded to at least two anti-VEGF injections.
Previously known as the Port Delivery System (PDS) with ranibizumab, the new therapy (Susvimo) is designed for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, AMD.
This is the only FDA-approved therapy for wet AMD that offers as few as two treatments per year.
“Susvimo represents a major advancement in the treatment of retinal disease, and is an important new